LC
RAPT

Lindbrook Capital’s RAPT Therapeutics RAPT Stock Holding History

Lindbrook Capital’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$32.9K Buy
+3,375
New +$33.2K ﹤0.01% 1149
2022
Q4 		– Sell
-2
Closed – – 2978
2022
Q3 		$0 Buy
+2
New +$378 ﹤0.01% 2861

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Lindbrook Capital's RAPT Position: Q1 2025 in Review

Lindbrook Capital opened a new position in RAPT Therapeutics (RAPT) in Q1 2025: 3,375 shares worth $32.9K. The stake represents ﹤0.01% of the portfolio and ranks #1149 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in RAPT as recently as Q3 2022.

Lindbrook Capital first reported a position in RAPT in Q3 2022 and has held it in 2 quarters since. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Lindbrook Capital held 3,375 shares of RAPT Therapeutics worth $32.9K as of Q1 2025.
  • RAPT Therapeutics was a new Lindbrook Capital position in Q1 2025.
  • RAPT Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1149 holding.
  • Lindbrook Capital first reported a position in RAPT Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.